StoneWise Raises $100 Million to Support AI Drug Development Services
April 14, 2021 at 04:50 AM EDT
StoneWise, a Beijing company offering AI-based small molecule drug development services, raised $100 million in Series B and B+ rounds. Founded in 2018, StoneWise has built a smart drug development platform based on AI algorithms, computational chemistry, pharmaceutical chemistry and computational biology. The company says its technology promotes a development process that is more time-efficient and cost-effective. The B round was led by Legend Capital, while the B+ round was co-led by Greater Bay Area Homeland Development Fund and Lightspeed China . More details.... Share this with colleagues: // //